Compare SMX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMX | NEUP |
|---|---|---|
| Founded | N/A | 1996 |
| Country | Ireland | United States |
| Employees | 19 | 8 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 23.1M |
| IPO Year | N/A | N/A |
| Metric | SMX | NEUP |
|---|---|---|
| Price | $15.65 | $3.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 44.7K | ★ 97.5K |
| Earning Date | 04-23-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $3.19 |
| 52 Week High | $490.00 | $21.31 |
| Indicator | SMX | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 31.65 |
| Support Level | $15.39 | $3.19 |
| Resistance Level | $17.72 | $4.58 |
| Average True Range (ATR) | 1.89 | 0.31 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 66.38 | 21.33 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.